Researchers found self-reported GLP-1 use climbed from March 2024 to October 2025, mostly for weight loss, through channels insurance data may not capture.
Recap by typeshit. Full story at News-Medical.
The review looks at concerns about misuse as demand for GLP-1 drugs grows, and points to how little evidence guides their use beyond approved conditions.
The study is looking for women with hot flashes and night sweats and a BMI above 30. Mayo Clinic has the full eligibility rules and how to sign up.
A matched cohort study in Inflammatory Bowel Diseases found remission odds nearly six times higher on GLP-1 drugs, and weight loss alone didn't explain it.
She says women with endometriosis taking GLP-1 drugs tell her bloating, pain and fatigue feel better. These are patient reports, not trial results.
The post warns that people in their 50s and 60s may blame vision changes on age or screens, when researchers have tied the drug in Ozempic to a rare cause of sudden sight loss.
The Illinois governor is speaking openly about his own GLP-1 use, saying he wants to end the stigma around the drugs. The post comes from a political fan page on Facebook.
Loading…